📊 Annual Industry Report · 2025

The State of Research Peptide Quality. 2025.

An independent dataset from 25000 research peptide samples submitted to Apollo Analytical during Jan 2024 – Dec 2024 — across 168 distinct suppliers. Free to share, cite, and republish with attribution.

Published Jun 2025 · CC BY 4.0 · Cite as: Apollo Analytical, State of Research Peptide Quality 2025.
25000
Samples Analyzed
168
Distinct Suppliers
62%
Overall Pass Rate
20%
Under-fill Defects

Pass rate by peptide class

Percent of samples meeting all release specifications (identity, purity, content, residuals). n shown per class.

GLP-1 analogs (Sema / Tirz / Reta)61% · n=7500
Growth hormone secretagogues65% · n=4700
Healing & repair peptides (BPC-157, TB-500)57% · n=3950
Melanocortin agonists (MT-2, PT-141)52% · n=2300
Nootropic / cognitive peptides63% · n=1950
Custom-synthesized (one-offs)76% · n=4600
Key Findings

Four conclusions from the 2024 dataset.

01

Pass rate climbed to 62% — a 4-point improvement over 2023.

Across 25,000 independently submitted samples, the overall pass rate rose meaningfully year-over-year, mostly on the back of fewer identity failures.

02

Under-fill overtook purity as the #1 defect.

For the first time in our dataset, stated-mass shortfalls beat HPLC purity gaps. Lyophilized fills from repeat suppliers were the worst offenders.

03

GLP-1 quality improved sharply.

Semaglutide / Tirzepatide / Retatrutide samples passed at 61%, up from 55% in 2023. Identity failures dropped notably as suppliers tightened SPPS protocols.

04

Independent third-party testing was still the only reliable filter.

Vendor self-reported COAs continued to over-state purity by an average of 2.7 percentage points relative to our re-analysis.

Defect Breakdown

How peptides actually fail.

A failing sample frequently fails more than one specification. Percentages below are share of all 25000 samples submitted, not share of failing samples.

Failure mode% of samples
Under-fill of stated mass (>10% short)
20%
HPLC purity below stated spec (>2% gap)
17%
Identity mismatch by ESI-MS
14%
Excess residual TFA (>1%)
8%
Endotoxin above injectable threshold
5%
Water content out of spec (Karl Fischer)
4%

Cite this report.

Released under Creative Commons Attribution 4.0. Republish, embed, or quote with a link back to this page.

Apollo Analytical (2025). The State of Research Peptide Quality 2025. Phoenix, AZ.
Retrieved from https://apolloanalytical.com/peptide-quality-report-2025